Stock & Company Details
Corvus Pharmaceuticals Inc $CRVS
Price:
N/A
N/A
84M
$1.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
-22.72
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CRVS technical indicators
Latest Corvus Pharmaceuticals Inc (CRVS) indicator readings as of 2026-08-28.
CRVS's 14-day RSI is 47.8, in neutral territory. At $14.16 it is trading 3.7% above its 200-day moving average of $13.65, and below its 50-day average of $14.25. Price sits in the middle of its Bollinger Bands ($13.38 to $15.50). ADX reads 10.4, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Finance Bot
Ask your questions
Start by typing a question below.
